Multiple sclerosis

References cited
Article section 15 of 16.  Previous  Next

By Anthony T Reder MD

Abu-Taha M, Rius C, Hermenegildo C, et al. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 2009;183(2):1393-402.

Acevedo AR, Nava C, Arriada N, Violante A, Corona T. Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand 2000;101:85-8.

Achiron A, Faibel M. Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiologic marker. Am J Neuroradiol 2002;23:376-80.

Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind placebo-controlled trial. Arch Neurol 2004;61(10):1515-20.

Ahn J, Feng X, Patel N, Dhawan N, Reder AT. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: Implications for control of apoptosis. Front Biosci 2004;9:1547-55.

Albert M, Antel J, Bruck W, Stadelmann C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 2007;17:129-38.**

Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE. Primary Sjogren's syndrome with central nervous system dysfunction mimicking multiple sclerosis. Ann Intern Med 1986;104:323-30.

Alter M, Kahana E, Zilber N, Miller A. Multiple sclerosis frequency in Israel's diverse populations. Neurology 2006;66:1061-6.

Alter M, Zhang ZX, Davanipour Z, et al. Multiple sclerosis and childhood infections. Neurology 1986;36:1386-9.

Alverdy J, Zaborina O, Wu L. The impact of stress and nutrition on bacterial-host interactions at the intestinal epithelial surface. Curr Opin Clin Nutr Metab Care 2005;8(2):205-9.**

Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010;75(20):1794-802.

Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-6.**

Andrews KL, Husmann DA. Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc 1997;72:1176-83.

Androdias G, Reynolds R, Chanal M, Ritleng C, Confavreux C, Nataf S. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol 2010;68(4):465-76.**

Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 2006;99(4):1073-87.

Anlar B, Gucuyener K, Imir T, Yalaz K, Renda Y. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double blind, placebo-controlled study. Pediatr Infect Dis 1993;12:578-81.

Antel JP, Arnason BG, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979;5:338-42.**

Antel JP, Bania MB, Reder AT, Cashman N. Activated suppressor cell dysfunction in chronic progressive multiple sclerosis. J Immunol 1986;137:137-41.

Applebee A, Panitch H. Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics 2009;3:257-71.**

Arnason BG. Depression in MS--Neuroimmunological perspective. Neuroimmune Biology 2005.**

Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002;58:S23-31.**

Arscott WT, Soltys J, Knight J, Mao-Draayer Y. Interferon β-1b directly modulates human neural stem/progenitor cell fate. Brain Res 2011;1413:1-8.

Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-32.

Astrom KE, Webster HD, Arnason BG. The initial lesion in experimental allergic neuritis: a phase and electron microscopic study. J Exp Med 1968;128(3):469-95.**

Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276-7.

Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16(4):406-12.**

Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000;192:393-404.

Bach JF. Mechanisms of disease: the effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.**

Bahmanyar S, Montgomery S, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009;72:1170-7.**

Bakshi R, Ariyaratana S, Benedict RH, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001;58:742-8.

Bakshi R, Minagar A, Jaisani Z, Wolinksy JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005;2(2):277-303.

Balabanov R, Strand K, Goswami R, et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci 2007;27:2013-24.

Balashov KE, Olek MJ, Smith DR, Khoury SJ, Weiner HL. Seasonal variation of interferon-gamma production in progressive multiple sclerosis. Ann Neurol 1998;44:824-8.

Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999;96:6873-8.

Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 1997;94:599-603.**

Bamford C, Sibley W, Laguna J. Anesthesia in multiple sclerosis. Can J Neurol Sci 1978;5:41-4.

Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321-37.

Bansil S, Lee HJ, Jindal S, Holtz CR, Cook SD. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol Scand 1999;99:91-4.

Banwell BL. Pediatric Multiple Sclerosis. Curr Neurol Neurosci Rep 2004;4:245-52.

Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006;66:472-6.

Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999;5:283-6.**

Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60(8):1073-81.**

Barkhof F, Hulst HE, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010;74(13):1033-40.

Barkhof F, van Waesberghe JH, Filippi M, et al. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001;124:1396-402.**

Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68.**

Bashir K, Whitaker JN. Importance of paraclinical and CSF studies in the diagnosis of MS patients presenting with partial cervical transverse myelopathy: cranial MRI. Mult Scler 2000;6:312-6.**

Baslow MH. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system: An analytical review. Neurochem Int 2002;40:295-300.

Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology 2012;78(24):1967-73.

Beatty WW. Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing. Mult Scler 1999;5:239-43.

Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-23.**

Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-810.**

Bennett JL, Haubold K, Ritchie AM, et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol 2008;199:126-32.**

Ben-Shlomo Y. Dietary fat in the epidemiology of multiple sclerosis: has the situation been adequately assessed? Neuroepidemiology 1992;11:214-25.**

Berg D, Supprian T, Thomae J, et al. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000;6:156-62.

Bergers E, Bot JC, De Groot CJ, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002;59:1766-71.

Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neuro Neurosurg Psychiatry 2002;73:148-53.

Betts CD. Bladder and sexual dysfunction in multiple sclerosis. In: Fowler CJ, editor. Neurology of bladder, bowel, and sexual dysfunction. Woburn: Butterworth-Heinemann, 1999;23:289-308.

Bibani RH, Tench CR, George J, Manouchehrinia A, Palace J, Constantinescu CS. Reduced EDSS progression in MS patients treated with modafinil for three years or more compared to matched untreated subjects. MS and Related Disorders 2012;1:131-5.

Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004;172:3893-4.

Biernacki K, Antel JP, Blain M, Narayanan S, Arnold DL, Prat. A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005;62:563-8.

Billiau A, Kieseier BC, Hartung HP. Biologic role of interferon beta in multiple sclerosis. J Neurol 2004;251(Supp 2):II/10-4.

Birk K, Ford C, Smeltzer S, Ryan D, Miller R, Rudick RA. The clinical course of multiple sclerosis during pregnancy and the puerperium. Arch Neurol 1990;47:738-42.**

Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin increases disease activity in multiple sclerosis. Neurology 2008;71(18):1390-5.**

Birnbaum G, Kotilinek L, Schlievert P, et al. Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): immunization with a peptide of the myelin protein 2’, 3’ cyclic nucleotide 3’ phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE. J Neurosci Res 1996;44:381-96.

Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000;123:1174-83.**

Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-8.**

Bloom PM, Reder AT. Treatment of multiple sclerosis with intense lymphocytapheresis (LCP), azathioprine, and oral prednisone. Neurology 2006;66(6 Suppl 1):A31, P31.077.

Booss J, Esiri MM, Tourtellotte WW, Mason DY. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983;62:219-32.

Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226-33.

Boullerne AI, Rodriguez JJ, Touil T, et al. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci 2002;22:123-32.

Boutros T, Croze E, Yong VW. Interferon-beta in a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997;69:939-46.

Bowling AC, Stewart TM. Dietary Supplements and Multiple Sclerosis: a Health Professional's Guide. New York: Demos Medical Publishing Inc, 2004.**

Brass SD, Narayanan S, Antel JP, Lapierre Y, Collins L, Arnold DL. Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci 2004;31:225-8.

Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25.

Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12(2):143-8.

Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64.

Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFN-beta 1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001;57:2185-90.

Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 2000;6:808-11.

Brown WJ. The capillaries in acute and subacute multiple sclerosis plaques: a morphometric analysis. Neurology 1978;28:84-92.**

Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlations of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-93.**

Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-60.

Buljevac D, Hop W, Reedeker W, et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. Br Med J 2003;327:646-51.

Burgoon MP, Cohrs RJ, Bennett JL, et al. Varicella Zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol 2009;65:474-9.

Byskosh PV, Reder AT. Interferon-beta effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996;1:262-9.

Cabrera-Gomez JA, Echazabal-Santana N, Porrero-Martin P, et al. El interferon-alpha2b recombinante mejora la disfuncion cognitiva en pacientes con esclerosis multiple. Rev Neurol 2003;37:214-20.

Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72:1330-6.

Calabresi PA, Austin H, Racke MK, et al. Impaired renal function in progressive multiple sclerosis. Neurology 2002;59:1799-801.

Calabresi PA, Frank JA, Maloni HW, et al. Association between neutralizing antibodies to interferon beta and contrast enhancing lesions in multiple sclerosis patients. Neurology 1997;48:A80.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon-beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801.

Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-35.

Caplan LR. Evidence and the effective clinical neurologist: the 2009 H. Houston Merritt lecture. Arch Neurol 2011;68(10):1252-6.

Castaigne P, Lhermitte F, Escourolle R, Hauw JJ, Gray F, Lyon-Caen O. Les scleroses en plaques asymptomatiques. Rev Neurol 1981;137:729-39.

Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-39.**

Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 2012;78(23):1860-7.

Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001;124:2169-76.

Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002;346:165-73.**

Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342-52.

Chari DM, Zhao C, Kotter MR, Blakemore WF, Franklin RJ. Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system. J Neurosci Res 2006;83:594-605.**

Chiu AW, Richert N, Ehrmantraut M, et al. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol 2009;66:39-43.

Ciccarelli O, Altmann DR, McLean MA, et al. Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 2010;74(9):721-7.

Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650-3.

Claudio L, Raine CS, Brosnan CF. Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis. Acta Neuropathol 1995;90:228-38.

Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984;41:1270-2.

Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15.**

Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001;58:961-7.

Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87.

Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting multiple sclerosis. Neurology 2009;72:535-41.**

Comabella M, Lunemann JD, Rio J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009;132(Pt 12):3353-65.**

Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986;109:325-44.

Cook SD. Multiple sclerosis. Arch Neurol 1998;55:421-3.**

Cooke RG. MS in the Faroe Islands and the possible protective effect of early childhood exposure to the “MS agent.” Acta Neurol Scand 1990;82:230-3.

Constantinescu CS. Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Med Hypotheses 1995;45:455-8.

Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 2007;61:97-108.**

Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67(4):652-9.

Correale J, Gilmore W, Lopez J, Li SQ, McMillan M, Weiner LP. Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis. Nat Med 1996;2:1354-60.**

Correale J, Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol 2008;195:121-34.**

Cosnett JE. Multiple sclerosis and neuromyelitis optica. S Afr Med J 1981;60:249-51.

Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60(4):640-6.

Couturier N, Zappulla JP, Lauwers-Cances V, et al. Mast cell transcripts are increased within and outside multiple sclerosis lesions. J Neuroimmunol 2008;195:176-85.

Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002;8:2-9.**

Craelius W. Comparative epidemiology of multiple sclerosis and dental caries. J Epidemiol Community Health 1978;32:155-65.

Craner MJ, Damarjian TG, Liu S, et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005;49:220-9.

Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African-American patients with multiple sclerosis. Neurology 2006;66(Suppl 2):A225.

Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-2.

Cross AH, Trotter JL, Lyons JA. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001;112:1-14.

Croze E, Velichko S, Tran T, et al. Betaseron induces a novel alternate start transcript in cells obtained from relapsing-remitting multiple sclerosis patients and human brain that is associated with control of oxidative resistance. Mult Scler 2009;15:P475, S138.

Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2012. [Epub ahead of print]

Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 1995;2:249-52.

Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine 2000;79:57-68.

Cummins TR, Renganathan M, Stys PK, et al. The pentapeptide QYNAD does not block voltage-gated sodium channels. Neurology 2003;60:224-9.**

Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005;65(12):1961-3.

Dahlslett SB, Goektas O, Schmidt F, Harms L, Olze H, Fleiner F. Psychophysiological and electrophysiological testing of olfactory and gustatory function in patients with multiple sclerosis. Eur Arch Otorhinolaryngol 2012;269(4):1163-9.

Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123:2407-22.**

Damek DM, Shuster EA. Pregnancy and multiple sclerosis. Mayo Clin Proc 1997;72:977-89.

Darabi K, Karulin AY, Boehn BO, et al. The third signal in T cell-mediated autoimmune disease. J Immunol 2004;173:92-9.

Daumer M, Neuhaus A, Morrissey S, Hintzen R, Ebers GC. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72(8):705-11.

Davies G, Keir G, Thompson EJ, Giovannoni G. The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology 2003;60:1163-6.

Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17.

Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology 1994;13:1-7.**

De Jager PL, Baecher-Allan C, Maier LM, et al. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci USA 2009;106(13):5264-9.

de Jong BA, Huizinga TW, Bollen EL, et al. Production of IL-1alpha and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002;126:172-9.

de Jong BA, Schrijver HM, Huizinga TW, et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann Neurol 2000;48:641-6.

De Keyser J, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999;53:1628-33.

Delalande S, de Seze J, Fauchais AL, et al. Neurological manifestations in Sjogren's syndrome (1). Clinical and biological findings in a cohort of 82 patients. Neurology 2003;60:A180.

Delasnerie-Laupretre N, Alperovitch A. Childhood infections in multiple sclerosis: a study of North African-born patients who migrated to France. The French Collaborative Group on Multiple Sclerosis. Neuroepidemiology 1990;9:118-23.

DeLuca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006;129:1507-16.**

Derecki NC, Cardani AN, Yang CH, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 2010;207(5):1067-80.

de Seze J, Arndt C, Stojkovic T, et al. Pupillary disturbances in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2001;188(1-2):37-41.

de Seze J, Delalande S, Michelin E, et al. Neurological manifestations in Sjogren's syndrome (2). MRI, CSF and outcome profiles in a cohort of 82 patients. Neurology 2003;60:A180.

de Seze J, Peoc'h K, Ferriby D, Stojkovic T, Laplanche JL, Vermersch P. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J Neurol 2002;249:626-7.

De Stefano N, Cocco E, Lai M, et al. Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 2006;59(4):634-9.

Detels R, Visscher BR, Malmgren RM, Coulson AH, Lucia MV, Dudley JP. Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. Am J Epidemiol 1977;105:303-10.

Dettke M, Scheidt P, Prange H, Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 1997;17:293-9.**

Dhaunchak AS, Becker C, Schulman H, et al. Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol 2012;71(5):601-13.

Dhawan N, Cheng H, Reder AT. Statins block interferon signaling in human immune cells: Potential loss of the therapeutic effect of IFN-beta in multiple sclerosis. Neurology 2007;68:S59.005, A364.

Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci 2003;23:6993-7000.

Diem R, Sättler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2004;128:375-85.

Dore-Duffy P, Donaldson JO, Koff T, Longo M, Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986;36:1587-90.

Dressel A, Mirowska-Guzel D, Gerlach C, Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol Scand 2007;116(3):164-8.

Duddy ME, Armstrong MA, Crockard AD, Hawkins SA. Changes in plasma cytokines induced by interferon-beta 1a treatment in patients with multiple sclerosis. J Neuroimmunol 1999;101:98-109.

Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-9.

Duquette P, Murray TJ, Pleines J, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr 1987;111:359-63.**

Duran I, Martinez-Caceres EM, Rio J, Barbera N, Marzo ME, Montalban X. Immunological profile of patients with primary progressive multiple sclerosis: expression of adhesion molecules. Brain 1999;122:2297-307.

Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509.**

Durfee J, Weinstock-Guttman B, Stosic M, et al. Cigarette smoking accelerates the evolution of brain atrophy and influences the severity of blood-brain-barrier disruption in multiple sclerosis. Neurology 2008;70:A465, P08.147.

Dutt M, Tabuena P, Ventura E, Rostami A, Shindler KS. Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis. Invest Ophthalmol Vis Sci 2010;51(3):1439-45.

Dworkin RH, Bates D, Millar JH, Paty DW. A re-analysis of three double-blind trials. Neurology 1984;34:1441-5.**

Ebers GC. The natural history of multiple sclerosis. Neurol Sci 2000;21:S815-7.**

Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in multiple sclerosis clinical trials. Neurology 2008;71(9):624-31.

Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain 2000;123 Pt 3:641-9.

Ebers GC, PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon-beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.

Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 1993;12:1-5.**

Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81(8):907-12.**

Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63.

Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-41.

Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49:67-79.

Eskan MA, Rose BG, Benakanakere MR, Lee MJ, Kinane DF. Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J Immunol 2008;180:1818-25.

Fassbender K, Schmidt R, Mossner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 1998;55:66-72.

Favorova OO, Andreewski TV, Boiko AN, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 2002;59:1652-5.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.**

Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008;71:265-71.

Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586-90.

Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Invest 1992;70:28-37.

Feng X. Complex immunomodulatory effects of IFN-beta therapy in multiple sclerosis. NeuroBase/Neurology MedLink 2001.

Feng X, Han D, Kilaru BK, Franek BS, Niewold TB, Reder AT. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol 2012b:1-7.

Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Decreased expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002a;129:105-15.**

Feng X, Reder NP, Yanamandala M, et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 2012a;313(1-2):48-53.

Feng X, Yau D, Holbrook C, Reder AT. Type I interferons inhibit IL-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002b;22(3):311-9.

Files JG, Hargrove D, Delute L, Cantillon M. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 2007;27:637-42.

Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-7.**

Filippi M, Rocca MA, Camesasca F, et al. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76(14):1222-8.**

Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-3.**

Filippi M, Tortorella C, Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Mult Scler 1999;5:273-82.**

Firth D. The case of Augustus D'Este. Great Britain: Cambridge University Press, 1948:1-59.**

Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000;48:885-92.

Fisher E, Chang A, Fox RJ, et al. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007;62:219-28.

Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3):255-65.**

Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17.

Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001;7:327-34.

Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 2006;67(11):2085-6.**

Francis G, Rice G, Alsop J, et al. Interferon beta-1a in MS. Neurology 2005;65:48-55.

Franklin GM, Tremlett H. Multiple sclerosis and pregnancy: what should we be telling our patients? Neurology 2009;73(22):1820-2.

Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008;9(11):839-55.

Fredrikson S, Soderstrom M, Hillert J, Sun JB, Kall TB, Link H. Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members. Acta Neurol Scand 1994;89:184-9.**

Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005;62:865-70.

Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis. Arch Neurol 2005;62:1345-56.

Frohman TC, Galetta S, Fox R, et al. Pearls & Oy-sters: the medial longitudinal fasciculus in ocular motor physiology. Neurology 2008;70:e57-67.**

Frohman EM, Havrdova E, Lublin F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006;63(4):614-9.

Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8(4):227-36.

Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 2000;55:1566-8.

Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001;124(Pt 11):2162-8.

Fulton JC, Grossman RI, Mannon LJ, Udupa J, Kolson DL. Familial multiple sclerosis: volumetric assessment in clinically symptomatic and asymptomatic individuals. Mult Scler 1999;5:74-7.

Furlan R, Brambilla E, Ruffini F, et al. Intrathecal delivery of IFN-gamma protects C57 BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001;167:1821-9.**

Gaitan MI, Shea CD, Evangelou IE, et al. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70(1):22-9.

Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15(1):50-8.

Garner DJ, Widrick JJ. Cross-bridge mechanisms of muscle weakness in multiple sclerosis. Muscle Nerve 2003;27:456-64.

Garren H, Robinson WH, Krasulová E, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63:611-20.

Gass A, Kitchen N, MacManus DG, Moseley IF, Hennerici MG, Miller DH. Trigeminal neuralgia in patients with multiple sclerosis: lesion localization with magnetic resonance imaging. Neurology 1997;49:1142-4.

Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992;258:1491-4.**

Gay F. Bacterial toxins and multiple sclerosis. J Neurol Sci 2007;262:105-12.

Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997;120(Pt 8):1461-83.

Ge Y, Law M, Herbert J, Grossman RI. Prominent perivenular spaces in multiple sclerosis as a sign of perivascular inflammation in primary demyelination. AJNR Am J Neuroradiol 2005;26(9):2316-9.

Genc K, Altungoz O, Pekcetin C. The effect of IFN-beta on IFN gamma-induced B7 costimulation molecule expression on microglial cells in vitro. Mult Scler 1997a;3:312.

Genc K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis, and reversal by interferon beta-1b therapy. J Clin Invest 1997b;99:2664-71.

Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res 2004;1000:19-31.

Georgi VW. Multiple sklerose: pathologisch-anatomische Befunde multipler sklerose bei klinisch nicht diagnostizierten Krankheiten. Schweiz Med Wochenschr 1961;91:605-7.**

Gershon MD, Kirchgessner AL, Wade PR. Functional anatomy of the enteric nervous system. In: Johnson LR, editor. Physiology of the gastrointestinal tract. New York: Raven Press, 1994:381-422.

Geurts JJ, Bo L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007;66:819-27.**

Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999;246:770-5.**

Ghoreishi M, Bach P, Obst J, et al. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J Immunol 2009;182:6071-8.

Giess R, Maurer M, Linker R, et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002;59:407-9.**

Gilbert JJ, Sadler M. Unsuspected multiple sclerosis. Arch Neurol 1983;40:533-6.

Gillson G, Richard TL, Smith RB, Wright JV. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 2002;8:30-5.

Gironi M, Martinelli V, Brambilla E, et al. Beta-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis: effects of treatment with interferon beta. Arch Neurol 2000;57(8):1178-81.

Giorelli M, Livrea P, Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from multiple sclerosis patients. J Neuroimmunol 2004;155:143-9.

Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol 2008;64:143-8.

Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2001;58:169-78.**

Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007a;68:977-84.**

Goodin DS, Hartung HP, O'Connor P, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler 2012a;18(2):181-95.

Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon-beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 2007b;35:173-87.

Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012b;78(17):1315-22.**

Goodkin DE. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000;54:2352.

Goodkin DE, Hertsgaard D. Seasonal variation of multiple sclerosis exacerbations in North Dakota. Arch Neurol 1989;46:1015-8.**

Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Arch Neurol 1989;46:1107-12.**

Goodkin DE, Rooney WD, Sloan R. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998;51:1689-97.

Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993;72:551-60.**

Group CHAMPS. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002;59:998-1005.

Gruenwald I, Vardi Y, Gartman I, et al. Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler 2007;13:95-105.

Gulcher JR, Vartanian T, Stefansson K. Is multiple sclerosis an autoimmune disease. Clin Neurosci 1994;2:246-52.

Gunal DI, Afsar N, Tanridag T, Aktan S. Autonomic dysfunction in multiple sclerosis: correlation with disease-related parameters. Eur Neurol 2002;48:1-5.

Gunnarsson M, Malmestrom C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011;69(1):83-9.**

Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 1995;129(1):1-8.

Haas J, Fritzsching B, Trubswetter P, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007;179:1322-30.

Haas J, Korporal M, Balint B, Fritzsching B, Schwarz A, Wildemann B. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis. J Neuroimmunol 2009;216(1-2):113-7.

Hamamcioglu K, Reder AT. Current perspectives in the pathogenesis and treatment of multiple sclerosis. Turk J Med Sci 2005;35:131-41.

Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007;13(4):459-70.

Harding AE, Sweeney MG, Miller DH, et al. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979-89.**

Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88.**

Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-52.

Hedstrom AK, Akerstedt T, Hillert J, Olsson T, Alfredsson L. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol 2011;70(5):733-741.**

Heesen C, Gold SM, Sondermann J, Tessmer W, Schulz KH. Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFN-gamma) release in multiple sclerosis patients and controls. J Neuroimmunol 2002;132(1-2):189-95.

Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology 2007;68:376-83.

Hernan MA, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006;67(2):212-5.

Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004;63:838-42.

Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 2001;154:69-74.**

Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of MS in a population-based Canadian cohort. Naurology 2007;69(12):1208-12.

Hesse D, Krakauer M, Lund H, et al. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology 2010;74(18):1455-62.

Hickey WF. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol 1999;98:37-44.**

Hirotani M, Maita C, Iguchi-Ariga SM, et al. Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult Scler OnlineFirst 2008;14(8):1056-60.

Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280-7.

Hogancamp WE, Rodriguez M, Weinshenker BG. The epidemiology of multiple sclerosis. Mayo Clin Proc 1997;72:871-8.**

Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000;107:161-6.**

Hosback S, Hardiman O, Nolan CM, et al. Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis. Growth Horm IGF Res 2007;17:472-9.

Hug A, Korporal M, Schroder I, et al. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J Immunol 2003;171(1):432-7.**

Huisinga JM, Filipi ML, Stergiou N. Elliptical exercise improves fatigue ratings and quality of life in patients with multiple sclerosis. J Rehabil Res Dev 2011;48(7):881-90.

Huitinga I, Erkut ZA, van Beurden D, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004;55:37-45.

Hulshof S, Montagne L, De Groot CJ, Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 2002;38:24-35.

Hulst HE, Schoonheim MM, Roosendaal SD, et al. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Hum Brain Mapp 2012;33(10):2268-80.

Ibrahim MZ, Reder AT. The mast cells of the multiple sclerosis brain. J Neuroimmunol 1996;70:131-8.*

Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 2008;131:785-99.

Ioannou M, Alissafi T, Lazaridis I, et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 2012;188(3):1136-46.

Ishizu T, Osoegawa M, Mei F, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128:988-1002.

Ivanov, II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-49.

Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-43.

Javed A, Balabanov R, Arnason BG, et al. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 2008;14(6):809-14.**

Javed A, Reder AT. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther 2006;110(1):35-56.

Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler 2010;16(1):30-8.

Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand 1982;65:182-9.

John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nature Med 2002;8:1115-20.**

Jones TB, Ankeny DP, Guan Z, et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J Neurosci 2004;24:3752-61.

Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68:283-7.

Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendrocrinology 2002;27:671-81.

Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532-3.

Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 2006;12(1):58-65.

Kampman MT, Steffensen LH. The role of vitamin D in multiple sclerosis. J Photochem Photobiol B 2010;101(2):137-41.**

Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002;123:144-59.

Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 2003;61:238-40.

Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003;53:174-80.

Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9(7):681-8.**

Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97.**

Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on Interferon beta-1b in secondary-progressive MS. Neurology 2001;57:1969-75.**

Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.**

Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 2002;109:641-9.**

Karaszewski JW, Reder AT, Anlar B, Kim WC, Arnason BG. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol 1991;30:42-7.

Karaszewski JW, Reder AT, Maselli R, Brown M, Arnason BG. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990;27:366-72.**

Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-202.

Keane JR. Internuclear ophthalmoplegia. Arch Neurol 2005;62:714-7.

Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366(9485):579-82.**

Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-6.

Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18-27.**

Khan OA, Dhib-Jalbut SS. Serum interferon beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998;51(3):738-42.

Khatibi E, Reder AT. The activating Zeta chain of the T cell receptor is increased on MS lymphocytes. Mult Scler 2008;14:P719, S241.

Khatri BO, McQuillen MP, Hoffmann RG, Harrington GJ, Schmoll D. Plasma exchange in chronic progressive multiple sclerosis: a long-term study. Neurology 1991;41:409-14.

Khoury SJ, Healy BC, Kivisakk P, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 2010;67(9):1055-61.

Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004;61(6):929-32.

Killestein J, Eikelenboom MJ, Izeboud T, et al. Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. J Neuroimmunol 2003;142(1-2):141-8.

Killestein J, Hintzen RQ, Uitdehaag BM, et al. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J Neuroimmunol 2002a;133(1-2):217-24.

Killestein J, Rep MH, Meilof JF, et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002b;58:1077-80.

Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004;172:7144-53.

Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001;65:510-16.

Kira J, Kanai T, Nishimura Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-74.

Kira J, Yamasaki K, Horiuchi I, Ohyagi Y, Taniwaki T, Kawano Y. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999;166:53-7.**

Kirk S, Frank JA, Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J Neurol Sci 2004;217:125-30.

Kivisakk P, Mahad DJ, Callahan MK, et al. Expression of CR7 in multiple sclerosis: implications for CNMS immunity. Ann Neurol 2004;55:627-38.

Kivisakk P, Tian W, Matusevicius D, Link H, Soderstrom M. Optic neuritis and cytokines. No relation to MRI abnormalities and oligoclonal bands. Neurology 1998;50:217-23.

Kleeberg J, Bruggimann L, Annoni J-M, van Melle G, Bogousslavsky J, Schluep M. Altered decision-making in multiple sclerosis: a sign of impaired emotional reactivity. Ann Neurol 2004;56:787-95.

Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States. Neurology 2006;66:1696-1702.

Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9.**

Konig FB, Wildemann B, Nessler S, et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008;65:1527-32.

Korporal M, Haas J, Balint B, et al. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol 2008;65(11):1434-9.

Korteweg T, Tintore M, Uitdehaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006;5(3):221-7.

Kovacs GG, Hoftberger R, Majtenyi K, et al. Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005;128 (Pt 1):35-41.

Kowarik MC, Pellkofer HL, Cepok S, et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 2011;76(14):1214-21.**

Kracke A, von Wussow P, Al Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000;54:193-9.**

Kraus J, Kuehne KJ, Tofighi J, et al. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Acta Neurol Scand 2002;105:300-8.

Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122(Pt 10):1941-50.

Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-94.

Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291:427-34.

Krupp LB, Christodoulou C. Fatigue in multiple sclerosis. Curr Neurol Neurosci Rep 2001;1:294-8.

Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011;76(17):1500-7.

Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-12.**

Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact 2000;16:226-8.

Kumpfel T, Hoffmann LA, Pellkofer H, et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 2008;71:1812-20.

Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975;51:110-36.**

Kurtzke JF. Multiple sclerosis: changing times. Neuroepidemiology 1991;10:1-8.**

Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427.**

Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29:1228-35.

Kurtzke JF, Hyllested K, Heltberg A, Olsen A. Multiple sclerosis in the Faroe Islands: 5. The occurrence of the fourth epidemic as validation of transmission. Acta Neurol Scand 1993;88:161-73.

Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions: an immunohistochemical study. J Neuropathol Exp Neurol 1994;53:625-36.

Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology 2011;77(12):1143-8.

Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18(4):563-76, ix.**

Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17:210-8.

Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;36:S42-6.**

Law M, Saindans AM, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004;231:645-52.

Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humor immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14(4):461-70.

Lebrun C, Bensa C, Debouverie M, et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 2008;79:195-8.

Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis. Brain 1999;122:1261-70.

Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain-barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007;33(1):86-98.

Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001;58:57-60.

Leocani L, Comi G. Neurophysiological investigations in multiple sclerosis. Curr Opin Neurol 2000;13:255-65.**

Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46(2):197-206.

Li J, Johansen C, Bronnum-Hansen H, Stenager E, Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents: a nationwide cohort study in Denmark. Neurology 2004;62:726-9.

Lin W, Bailey SL, Ho H, et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest 2007;117:448-56.

Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998;4(1):12-5.

Linker RA, Gaupp S, Holtmann B, et al. CNTF-deficiency deteriorates clinical course and histopathology in a murine model of experimental autoimmune encephalomyelitis: a neurotrophic factor as outcome determinator of neuroinflammation. Neurology 2001;56:A67.

Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006;12:518-25.

Love S, Coakham HB. Trigeminal neuralagia: pathology and pathogenesis. Brain 2001;124(Pt 12):2347-60.

Lu CZ, Jensen MA, Arnason BG. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol 1993;46:123-8.

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32.

Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011;76(6):540-8.**

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 1999;122:2279-95.

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.**

Ludwin SK. The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 2006;65:305-18.*

Lyons PD, Blalock JE. Pre-opiomelanocortin gene expression and protein processing in rat mononuclear leukocytes. J Neuroimmunol 1997;78:47-56.

MacPherson A, Dinkel K, Sapolsky R. Glucocorticoids worsen excitotoxin-induced expression of pro-inflammatory cytokines in hippocampal cultures. Exp Neurol 2005;194(2):376-83.

Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and sera of patients with multiple sclerosis. J Neuroimmunol 1991a;32:67-74.

Maimone D, Reder AT. Soluble CD8 levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. Neurology 1991;41:851-4.

Maimone D, Reder AT, Finocchiaro F, Recupero E. Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol 1991b;48:427-9.

Manavalan JS, Kim-Schulze S, Scotto L, et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ LT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004;16:1055-68.

Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-8.

Manrique-Hoyos N, Jurgens T, Gronborg M, et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012;71(2):227-44.**

Marmor M, Sheppard HW, Donnell D, et al. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J Acquir Immune Defic Syndr 2001;27:472-81.

Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races. Neurology 2006;66:1235-40.

Marrie RA, Fisher E, Miller DM, Lee JC, Rudick RA. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 2005;228:161-6.

Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010;185(2):1311-20.

Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. Myelin basic protein-specific T cell responses in identical twins discordant or concordant for multiple sclerosis. Ann Neurol 1993;34:524-35.

Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008;38:576-86.

Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol 2010;6(5):247-55.**

Martino G, Molola L, Brambilla E, Clementi E, Comi G, Grimaldi LM. Gamma-interferon induces T- lymphocyte proliferation in multiple sclerosis via a calcium-dependent mechanism. J Neuroimmunol 1995;62:169-76.

Mastronardi FG, Min W, Wang H, et al. Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1/sonic hedgehog balance. J Immunol 2004;172:6418-26.

Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A. Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol 2010;6(8):455-61.

Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.

Mattson DH, Roos RP, Arnason BG. Isoelectric focusing of IgG eluted from multiple sclerosis, subacute sclerosing panencephalitis and normal brains. Nature 1980;287:335-7.**

Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4.

Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003;61:1373-7.

McAlpine D, Compston ND, Acheson E. Multiple sclerosis: a reappraisal. Edinburgh and London: Livingstone, 1972.

McDonald WI, Barnes D. Lessons from magnetic resonance imaging in multiple sclerosis. Trends Neurosci 1989;12:376-9.

McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.**

Meaney JF, Watt JW, Eldridge PR, Whitehouse GH, Wells JC, Miles JB. Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. J Neurol Neurosurg Psychiatry 1995;59:253-9.

Medaer R. Does the history of multiple sclerosis go back as far as the 14th century? Acta Neurol Scand 1979;60:189-92.**

Meier DS, Weiner HL, Guttmann CR. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol 2007;28:1956-63.

Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880-92.

Mesaros S, Rocca MA, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology 2012;78(13):969-75.

Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nature Med 2007;13:1228-33.**

Mian MF, Stampfli MR, Mossman KL, Ashkar AA. Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Mol Immunol 2009;46(5):821-9.

Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.**

Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012;11(2):131-9.

Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71.

Mitsdoerffer M, Schreiner B, Kieseier BC, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005;159:155-64.

Mohr DC, Goodkin DE, Bacchetti P, et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 2000;55:55-61.

Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis. Arch Neurol 2001;58:1081-6.

Mold JE, Michaelsson J, Burt TD, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008;322:1562-5.

Moll HP, Freudenthaler H, Zommer A, Buchberger E, Brostjan C. Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J Immunol 2008;180:5250-6.

Monson NL, Brezinschek HP, Brezinschek RI, et al. Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 2004;158:170-81.

Mostert JP, Admiraal-Behloul F, Hoogduin JM, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 2008;79(9):1027-31.

Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology 1988;38:1830-4.**

Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011;364(25):2392-404.

Muller DM, Pender MP, Greer JM. Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 2005;160:162-9.

Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-5.

Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5.

Murphy CB, Hashimoto SA, Grach D, Thiessen BA. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol 2003;60:273-5.

Murray TJ. Multiple Sclerosis: the History of a Disease. New York: Demos Medical Publishing, 2005.**

Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009;73(1):46-52.

Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-86.**

Natowicz MR, Bejjani B. Genetic disorders that masquerade as multiple sclerosis. Am J Med Genet 1994;49:149-69.**

Nelson LM, Franklin GM, Jones MC. Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. JAMA 1988;259:3441-3.

Ness JM, Chabas D, Sadovnick AD, et al. Clinical features of children and adolescents with multiple sclerosis. Neurology 2007;68:S37-45.**

Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta1b in MS. Neurology 2002;59:990-7.

Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012;78(2):91-101.

Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007;117:2553-61.

Nishino H, Hashitani T, Kumazaki M, et al. Long-term survival of grafted cells, dopamine synthesis/release, synaptic connections, and functional recovery after transplantation of fetal nigral cells in rats with unilateral 6-OHDA lesions in the nigrostriatal dopamine pathway. Brain Res 1990;534(1-2):83-93.

Nisipeanu P, Korczyn AD. Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 1993;43:1311-2.**

Noronha A, Richman DP, Arnason BG. Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis. New Engl J Med 1980;303:713-7.

Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207-10.**

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.**

Nouri-Shirazi M, Guinet E. Exposure to nicotine adversely affects the dendritic cell system and compromises host response to vaccination. J Immunol 2012;188(5):2359-70.

Nozaki I, Hamaguchi T, Komai K, Yamada M. Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 2006;77:1094-5.

Ochi H, Feng-Jun M, Osoegawa M, et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci 2004;222(1-2):65-73.

Ochi H, Wu XM, Osoegawa M, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol 2001;119(2):297-305.

O‘Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76(22):1858-65.

Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993;43:905-9.

Oger J, Vorobeychick G, Paty DW. IGG secretion in vitro in relation with antibody status in MS patients treated with interferon beta 1B. Mult Scler 1997;3:406.

Oikonen MK, Eralinna JP. Beta-interferon protects multiple sclerosis patients against enhanced susceptibility to infections caused by poor air quality. Neuroepidemiology 2008;30:13-9.

Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-5.**

Olafson RA, Rushton JG, Sayre GP. Trigeminal neuralgia in patients with multiple sclerosis: an autopsy report. J Neurosurg 1966;24:755-9.

Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006;5:932-6.

Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009;73(18):1485-92.

Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005;26:341-6.

Page WF, Kurzke JF, Murphy FM, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann Neurol 1993;33:632-9.**

Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005;102(9):3372-7.

Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36:S25-S8.

Panitch H, Miller A, Paty D, Weinshenker B, and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 2004;63:1788-95.

Panitch HS, Bever CT, Katz E, Johnson KP. Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon. J Neuroimmunol 1991;(Suppl 1):125.**

Pantano P, Caramia F, Piattella MC, et al. From new enhancing lesions to “black holes” in patients with clinically isolated syndrome suggestive of multiple sclerosis. J Neurol 2001;248:302.

Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.

Parkin PJ, Hierons R, McDonald WI. Bilateral optic neuritis: a long-term follow-up. Brain 1984;107:951-64.

Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-9.

Parry A, Corkill R, Blamire AM, et al. Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 2003;250:171-8.

Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006;129(Pt 12):3165-72.**

Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010;16(1):68-77.

Patti F, Reggio E, Palermo F, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 2004;251(12):1502-6.

Pedotti R, DeVoss JJ, Youssef S, et al. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA 2003;100:1867-72.

Perini P, Wadhwa M, Buttarello M, et al. Effect of Interferon-beta and anti-Interferon-beta antibodies on NK cells in multiple sclerosis patients. J Neuroimmunol 2000;105:91-5.**

Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.

Petkau AJ, White R, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-38.

Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-628.

Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68(5):693-702.

Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort. Neurology 2004;62:51-9.

Pittock SJ, Weinshenker BG, Noseworthy JH, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006;63(4):611-4.

Piyasirisilp S, Schmeckpeper BJ, Chandanayingyong D, Hemachudha T, Griffin DE. Association of HLA and T cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann Neurol 1999;45:595-600.**

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302.

Pliskin NH, Reder AT, Goldstein DS. Neuropsychological effects of interferon therapy. In: Reder AT, editor. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997.

Ponsonby AL, van der Mei I, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 2005;293:463-9.

Poser CM. Pathogenesis of multiple sclerosis. Acta Neuropathol 1986;71:1-10.

Poser CM, Paty DW, Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.

Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study. Neurology 2012;78(12):867-74.

Pozzilli C, Falaschi P, Mainero C, et al. MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns. Neurology 1999;53:622-4.

Prat A, Biernacki K, Antel JP. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun 2005;24(2):119-24.**

Prat A, Biernacki K, Becher B, Antel JP. B7 expression and antigen presentation by human brain endothelial cells: requirement for proinflammatory cytokines. J Neuropathol Exp Neurol 2000a;59:129-36.

Prat A, Pelletier D, Duquette P, Arnold DL, Antel JP. Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. Ann Neurol 2000b;47:234-7.

Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979;203:1123-5.**

Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137-51.**

Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91.**

Pujol J, Bello J, Deus J, Marti-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997;49:1105-10.

Pulizzi A, Rovaris M, Judica E, et al. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007;64:1163-8.

Qiu J, Cai D, Dai H, et al. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 2002;34:895-903.

Ragheb S. Multiple sclerosis: genetic background versus environment. Ann Neurol 1993;34:509-10.

Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011;17(7):819-29.

Raine CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991;17:265-74.**

Ramagopalan SV, Yee IM, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. Neurology 2009;73(8):602-5.

Rammohan KW. Axonal injury in multiple sclerosis. Curr Neurol Neurosci Rep 2003;3(3):231-7.

Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-91.**

Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995;4:415-8.

Reder AT. Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology 1992;77:436-42.

Reder AT. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997:549.**

Reder AT. Neutralizing antibodies in multiple sclerosis: A complex impact on interferon responses, magnetic resonance imaging findings, and clinical outcomes. Mult Scler 2007;13:553-62.**

Reder AT. MxA: a biomarker for predicting multiple sclerosis disease activity. Neurology 2010;75(14):1222-3.

Reder AT, Antel JP. Clinical spectrum of multiple sclerosis. Neurol Clin 1983;1:573-99.**

Reder AT, Arnason BG. Immunology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, Koetsier JC, editors. Handbook of clinical neurology: demyelinating diseases. Amsterdam: North Holland Publishing, 1985:337-95.**

Reder AT, Arnason BG. Trigeminal neuralgia in MS relieved by a prostaglandin E analogue. Neurology 1995;45:1097-100.

Reder AT, Arnason BG, Maimone D, Rohwer-Nutter D. The function of the CD2 protein is abnormal in multiple sclerosis. J Autoimmunity 1991;4:479-91.

Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010;74(23):1877-85.**

Reder AT, Goodin DS, Ebers GC, et al. Clinical outcomes and cause of death for interferon beta-1b versus placebo, 21 years following randomization. Neurology 2012:P04.129.

Reder AT, Li L, Feng X. Disease activity affects responses to IFN-beta-1b therapy in multiple sclerosis. Neurology 2011;76:P01.215.

Reder AT, Lowy MT, Meltzer HY, Antel JP. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 1987;37:849-53.

Reder AT, Makowiec RL, Lowy M. Adrenal size is increased in multiple sclerosis. Arch Neurol 1994c;51:151-4.

Reder AT, Thapar M, Jensen M. A fall in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology 1994a;44:2289-94.

Reder AT, Thapar M, Sapugay AM, Jensen MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994b;54(1-2):117-27.

Reder AT, Velichko S, Yamaguchi KD, et al. Interferon-beta-1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients, independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008;28:317-31.

Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006;180(1-2):50-62.

Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047-56.

Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a “paravascular” fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985;326:47-63.

Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol 1992;40:225-30.

Rice GP. The evolution of neutralizing antibodies in patients taking beta interferon 1b. Mult Scler 1997;3:344.**

Riechert T, Hassler R, Mundinger F, Bronisch F, Schmidt K. Pathologic-anatomical findings and cerebral localization in stereotactic treatment of extrapyramidal motor disturbances in multiple sclerosis. Confin Neurol 1975;37:24-40.

Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-6.**

Riesbeck K. Immunomodulating activity of quinolones: review. J Chemother 2002;14:3-12.**

Rinker JR 2nd, Trinkaus K, Naismith RT, Cross AH. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology 2007;69:68-72.

Río J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15(7):848-53.

Rodrigo L, Hernandez-Lahoz C, Fuentes D, et al. Prevalence of celiac disease in multiple sclerosis. BMC Neurol 2011;11:31.

Rosenbluth J, Schiff R, Liang WL, Dou WK, Moon D. Antibody-mediated central nervous system demyelination: focal spinal cord lesions induced by implantation of an IgM antigalactocerebroside-secreting hybridoma. J Neurocytol 1999;28:397-416.**

Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12.**

Rothuizen LE, Buclin T, Spertini F, et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999;99:131-41.**

Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 1993;56:1062-5.

Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64(7):1144-51.

Rudick RA, Cookfair DL, Simonian NA, et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. J Neuroimmunol 1999;93:8-14.**

Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009;72(23):1989-93.

Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One 2011;6(5):e19262.**

Rudick RA, Ransohoff RM, Lee J-C, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998;50:1294-300.

Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis: the problem of incorrect diagnosis. Arch Neurol 1986;43:578-83.**

Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology 1999;53:478-84.

Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 1995;118:253-61.**

Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis: report of 35 cases. Arch Neurol 1965;13:383-6.

Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: A novel mediator of T cell tolerance. J Immunol 2005;175:7085-91.

Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998;44:980-3.

Sadovnick AD. Familial recurrence risks and inheritance of multiple sclerosis. Curr Opin Neurol Neurosurg 1993;6:189-94.

Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993;33:281-5.

Sadovnick AD, Duquette P, Herrera B, Yee IM, Ebers GC. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology 2007;69:60-2.

Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.

Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-6.

Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606.

Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology 2000;55:61-5.

Sakai S, Takaishi H, Matsuzaki K, et al. 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 2009;27(6):643-52.

Sandberg-Wollheim M, Axell T, Hansen BU. Primary Sjogren's syndrome in patients with multiple sclerosis. Neurology 1992;42:845-7.

Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings. Mult Scler 2011;17(4):431-40.**

Sapolsky RM. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp Gerontol 1999;34(6):721-32.

Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62:569-73.

Sattler MB, Demmer I, Williams SK, et al. Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 2006;201:172-81.

Sauer I, Schaljo B, Vogl C, et al. Interferons limit inflammatory responses by injuction of tristetraprolin. Blood 2006;107:4790-7.

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011;77(13):1246-52.

Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(Pt 7):1914-29.**

Schapiro R. Managing the Symptoms of Multiple Sclerosis. 4th ed. New York: Demos, 2003.**

Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 1998;5:147-60.**

Schoenberg H. Bladder and sexual dysfunction in multiple sclerosis. In: Antel JP, editor. Multiple sclerosis. Neurol Clin 1983;1:601-13.

Schonrock LM, Gawlowski G, Bruck W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 2000;294:45-8.

Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 2001;98:3398-403.**

Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology 1999;53:743-50.

Selby MJ, Ling N, Williams JM. Interferon beta 1-B in verbal memory functioning of patients with relapsing-remitting multiple sclerosis. Percept Mot Skills 1998;86:1099-1106.

Selcen D, Anlar B, Renda Y. Multiple sclerosis in childhood: report of 16 cases. Eur Neurol 1996;36:79-84.

Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-912.

Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74.**

Sharief MK. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J Neuroimmunol 2000;109:236-43.

Sibley WA. Risk factors in multiple sclerosis: implications for pathogenesis. In: Crescenzi GS, editor. A multidisciplinary approach to myelin diseases. New York: Plenum Publishing Corp., 1988:227-32.

Sibley WA. Physical trauma and multiple sclerosis. Neurology 1993;43:1871-4.**

Sibley WA. The effect of virus-like infections on the course of multiple sclerosis. In: Hommes OR, Wekerle H, Clanet M, editors. Genes and Viruses in Multiple Sclerosis. Elsevier Science BV, 2001:89-95.**

Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-5.**

Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455-61.**

Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000;55:185-92.

Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002;59:1922-8.

Siritho S, Freedman MS. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 2009;279(1-2):21-5.**

Siva A, Radhakrishnan K, Kurland LT, O'Brien PC, Swanson JW, Rodriguez M. Trauma and multiple sclerosis: a population-based cohort study from Olmsted County, Minnesota. Neurology 1993;43:1878-82.**

Skurkovich S, Boiko A, Beliaeva I, et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler 2001;7:277-84.

Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.

Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001;49:470-6.**

Smith PF, Darlington CL. Recent developments in drug therapy for multiple sclerosis. Mult Scler 1999;5:110-20.**

Smith R, Studd JW. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J R Soc Med 1992;85:612-3.

Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998;50:708-14.

Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83(5):565-71.**

Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004;146:209-15.

Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: Report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-27.*

Sorensen PS, Lycke J, Eralinna JP, et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011;10(8):691-701.**

Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362(9391):1184-91.

Sorensen PS, Tscherning T, Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 2006;67(9):1681-3.

Sormani MP, Bruzzi P, Beckmann K, et al. The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis. J Neurol 2005;252(12):1455-8.

Sormani MP, Li DK, Bruzzi P, et al. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology 2011;77(18):1684-90.

Sormani MP, Tintore M, Rovaris M, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol 2008;64:428-33.

Spadaro M, Amendolea MA, Mazzucconi MG, et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 1999;5:121-5.

Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005;128:979-87.*

Stankoff B, Mrejen S, Tourbah A, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology 2007;68:779-81.

Stapulionis R, Oliveira CL, Gjelstrup MC, et al. Structural insight into the function of myelin basic protein as a ligand for integrin alphaMbeta2. J Immunol 2008;180:3946-56.

Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129(Pt 5):1293-305.

Stenager EN, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991;84:197-200.

Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542-5.

Strasser-Fuchs S, Enzinger C, Ropele S, Wallner M, Fazekas F. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox? Mult Scler 2008;14:205-11.

Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, Deluca J. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler 2011;17(9):1141-5.

Susac JO, Murtagh FR, Egan RA, et al. MRI findings in Susac's syndrome. Neurology 2003;61:1783-7.**

Szuchet S, Nielsen JA, Lovas G, et al. The genetic signature of perineuronal oligodendrocytes reveals their unique phenotype. Eur J Neurosci 2011;34(12):1906-22.

Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127:1917-27.

Tan IL, van Schijndel RA, Pouwels PJ, et al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol 2000;21:1039-42.

Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176(11):7119-29.**

Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-9.

Then Bergh F, Kümpfelt T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of multiple sclerosis. Neurology 1999;53:772-7.

Then Bergh F, Kümpfelt T, Yassouridis A, et al. Acute and chronic neuroendocrine effects of interferon-beta-1a in multiple sclerosis. Clin Endocrinol 2007;66:295-303.

Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.

Thompson EJ, Freedman MS. Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Adv Neurol 2006;98:147-60.

Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64:1001-7.

Toledo J, Sepulcre J, Salinas-Alaman A, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 2008;14:906-12.

Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005;76:272-5.

Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.**

Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8(3):280-91.**

Traugott U, Scheinberg LC, Raine CS. On the presence of Ia-positive endothelial cells and astrocytes in multiple sclerosis lesions and its relevance to antigen presentation. J Neuroimmunol 1985;8:1-14.**

Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004;251:1297-303.

Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 2006;31:286-93.*

Trotter JL, Kelly GC, van der Veen RC. Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. J Neuroimmunol 1991;33:29-36.

Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355-67.

Tselis AC, Lisak RP. Acute disseminated encephalomyelitis and isolated central nervous system demyelinative syndromes. Curr Opin Neurol 1995;8:227-9.**

Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid-refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008;15:1163-7.

Tur C, Montalban X, Tintore M, et al. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol 2011;68(11):1421-7.**

Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-55.

Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012;78(1):15-23.

Uttner I, Muller S, Zinser C, et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005;64(11):1971-3.

van Boxel-Dezaire AH, van Trigt-Hoff SC, Killestein J, et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 2000;48(3):313-22.

van Boxel-Dezaire AH, Zula JA, Frost N, Ransohoff RM, Rudick RA, Stark GR. Ex vivo analysis of blood cells from IFN-beta-injected MS patients reveals differential STAT and kinase activation patterns. Cytokines 2006;17(Suppl):78.

van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype and risk of multiple sclerosis: case-control study. Br Med J 2003;327:316-20.

van der Voort LF, Vennegoor A, Visser A, et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 2010;75(14):1228-33.**

van Diemen HA, Lanting P, Koetsier JC, Strijers RL, van Walbeek HK, Polman CH. Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests. Clin Neurol Neurosurg 1992;94:191-5.

Van Weyenbergh J, Lipinski P, Abadie A, et al. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc-gamma receptor expression in healthy controls and multiple sclerosis patients. J Immunol 1998;161(3):1568-74.

Vedeler CA, Myhr KM, Nyland H. Fc receptors for immunoglobulin G--a role in the pathogenesis of Guillain-Barre syndrome and multiple sclerosis. J Neuroimmunol 2001;118:187-93.

Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206:43-9.

Venken K, Hellings N, Broekmans T, et al. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-20.

Vercellino M, Votta B, Condello C, et al. Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: a neuropathological study. J Neuroimmunol 2008;199:133-41.

Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256 Suppl 1:S5-13.**

Wainwright DA, Xin J, Sanders VM, Jones KJ. Differential actions of pituitary adenyl cyclase-activating polypeptide and interferon gamma on Th2- and Th1-associated chemokine expression in cultured murine microglia. J Neurodegen Regen 2008;1:1:31-4.

Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7.**

Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-57.**

Wang AG, Lin YC, Wang SJ, Tsai CP, Yen MY. Early relapse in multiple sclerosis-associated optic neuritis following the use of interferon beta-1a in Chinese patients. Jpn J Ophthalmol 2006;50:537-42.

Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252:57-61.

Warren KG, Catz I, Johnson E, Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280-9.

Watkins SM, Espir ML. Migraine and multiple sclerosis. J Neurol Neurosurg Psychiatry 1969;32:35-7.

Waubant E, du Montcel ST, Jedynak C, et al. Multiple sclerosis tremor and the Stewart-Holmes manoeuvre. Mov Disord 2003;18:948-52.

Waubant E, Mowry EM, Krupp L, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011;76(23):1989-95.

Waubant E, Pelletier D, Mass M, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 2012;78(15):1171-8.

Waxman SG. Ion channels and neuronal dysfunction in multiple sclerosis. Arch Neurol 2002;59:1377-80.

Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007a;4:647-53.

Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007b;13:935-43.

Weilbach FX, Toyka KV. Does Down's syndrome protect against multiple sclerosis. Eur Neurol 2002;47:52-5.**

Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142-54.

Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-61.**

Weinshenker BG, Lucchinetti CF. Acute leukoencephalopathies: differential diagnosis and investigation. Neurologist 1998;4:148-66.**

Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56:319-24.

Wellen J, Walter J, Jangouk P, Hartung HP, Dihne M. Neural precursor cells as a novel target for interferon-beta. Neuropharmacology 2009;56(2):386-98.

Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-80.

Whelan HT, Pledger WJ, Maciunas RJ, Galloway RL Jr, Whetsell WO Jr, Moses HL. Growth factors in the tumorigenicity of a brain tumor cell line. Pediatr Neurol 1989;5:271-9.

Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25.

Whitaker JN, Kachelhofer RD, Bradley EL, et al. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995;38:625-32.**

White DM, Jensen MA, Shi X, Qu Zx, Arnason BG. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors. Protein Expr Purif 2001;21:446-55.

Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:1107-14.

Wolinsky JS. Glatiramer acetate for the treatment of multiple sclerosis. Expert Opin Pharmacother 2004;5(4):875-91.

Wood DD, Bilbao JM, O'Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996;40:18-24.

Wu GF, Schwartz ED, Lei T, et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology 2007;69:2128-35.

Wuerfel J, Bellmann-Strobl J, Brunecker P, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004;127(Pt 1):111-9.

Wuerfel J, Haertle M, Waiczies H, et al. Perivascular spaces--MRI marker of inflammatory activity in the brain? Brain 2008;131(Pt 9):2332-40.

Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. Update on the epidemiology of multiple sclerosis. Mayo Clin Proc 1989;64:808-17.

Yamaguchi KD, Ruderman DL, Croze E, et al. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol 2008;195(1-2):116-20.**

Yang CC, Bowen JR, Kraft GH, Uchio EM, Kromm BG. Cortical evoked potentials of the dorsal nerve of the clitoris and female sexual dysfunction in multiple sclerosis. J Urol 2000;164(6):2010-3.

York NR, Mendoza JP, Ortega SB, et al. Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J Autoimmun 2010;35(1):33-44.

Ysrraelit MC, Gaitan MI, Lopez AS, Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology 2008;71:1948-54.**

Zeis T, Schaeren-Wiemers N. Lame ducks or fierce creatures? The role of oligodendrocytes in multiple sclerosis. J Mol Neurosci 2008;35:91-100.

Zeman AZ, Kidd D, McLean BN, et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:27-30.**

Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurology 2008;70(13 Pt 2):1092-7.**

Zipp F, Krammer PH, Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 1999;20:550-4.

Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci 2004;9:647-64.

Zivadinov R, Nasuelli D, Tommasi MA, et al. Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol Res 2006;28:262-9.

Zwemmer JN, Bot JC, Jelles B, Barkhof F, Polman CH. At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. Mult Scler 2008;14:428-30.

**References especially recommended by the author or editor for general reading.

In This Article

Historical note and nomenclature
Clinical manifestations
Clinical vignette
Pathogenesis and pathophysiology
Differential diagnosis
Diagnostic workup
Prognosis and complications
References cited